Cargando…
Rigosertib and Cholangiocarcinoma: A Cell Cycle Affair
Rigosertib is multi-kinase inhibitor that could represent an interesting therapeutic option for non-resectable patients with cholangiocarcinoma, a very aggressive hepatic cancer with limited effective treatments. The Western blotting technique was used to evaluate alterations in the expression of pr...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745771/ https://www.ncbi.nlm.nih.gov/pubmed/35008638 http://dx.doi.org/10.3390/ijms23010213 |